The Expression and Clinical Significance of CD90, IGF1R, and hTERT Protein in Hepatocellular Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHENG Suwen ¹ , ZHAO Hewei ¹ , WANG Wen ² , ZHANG Yewei. ¹

1. Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jiangsu Cancer Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China;;
2. Department of Ultrasound, Affiliated Hospital of Ningxia Medical University, Ningxia Muslim Population Autonomous Region, China;

Corresponding author：

Keywords：

Hepatocellular carcinoma; Tumor stem cell; Surface marker of stem cell; CD90; Insulin-like growth factor 1 receptor; Human telomerase reverse transcriptase

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To investigate the expressions of CD90, IGF1R, and hTERT protein in hepatocellular carcinoma, and the correlations of each other in the development of carcinoma.
Methods 　The expressions of CD90, IGF1R, and hTERT protein in hepatocellular carcinoma were detected by S-P immunohistochemical staining, 20 cases of normal liver tissues were collected as contrast, and to compare the relations between expression and prognosis or survival rate.
Results 　The positive rate of CD90, IGF1R, and hTERT protein in hepatocellular carcinoma group were obviously higher than that in contrast group（P＜0.05）, which was 63.9% vs. 0, 52.8% vs.5.0%, and 47.2% vs.0, respectively. The positive rate of CD90, IGF1R, and hTERT protein were higher in UICC Ⅲ-Ⅳ stage group than that in UICC stage Ⅰ-Ⅱ group（P＜0.05）, which was 79.2% vs.33.3%, 70.8% vs.16.7%, and 62.5% vs.16.7%, respectively. There was a statistically significant positive correlation observed between the expressions of CD90 and IGF1R protein （Kendall’s tau-b=0.563 1, P＜0.05）, so it was with CD90 and hTERT protein （Kendall’s tau-b=0.363 6, P＜0.05）. The survival rates of positive expressions of CD90, IGF1R, and hTERT protein were lower than negative expressions of CD90, IGF1R, and hTERT（P＜0.05）, which was 21.7% vs.50.0%, 17.6% vs.43.8%, and 20.0% vs.38.9%, respectively.
Conclusions 　The expressions of CD90, IGF1R, and hTERT may have correlations with the progress of HCC, and may serve as a marker for HCC prognosis potentially.

Citation： ZHENG Suwen,ZHAO Hewei,WANG Wen,ZHANG Yewei.. The Expression and Clinical Significance of CD90, IGF1R, and hTERT Protein in Hepatocellular Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(3): 271-276. doi: Copy

1.	Zhen FY， David WH， Michael NN， et al. Significance of CD90+cancer stem cells in human liver cancer [J]. Cancer Cell， 2008，13(2): 153-166.
2.	Kelly PN， Dakic A， Adams JM， et al. Tumor growth need not be riven by rare cancer stem cells [J]. Science， 2007， 317(7): 337-337.
3.	Bradley JE， Ramirez G， Hagood JS. Roles and regulation of Thy-1，a context-dependent modulator of cell phenotype [J]. Biofactors，2009， 35(3): 258-265.
4.	张华，高志红，刘春玲，等. Thy-1 肿瘤标记物在肝癌的表达及意义研究 [J]. 医学与哲学：临床决策论坛版， 2009， 30(5)：51-53．.
5.	牛坚，李向农，韩泽广. 运用siRNA 建立稳定低表达IGF1R基因的肝癌细胞株的实验研究 [J]. 中国普外基础与临床杂志， 2007， 14(6)：679-684．.
6.	Maki RG. Small is beautiful: insulin-like growth factors and their ole in growth， development， and cancer [J]. J Clin Oncol，2010， 28(33): 4985-4995.
7.	Li R， Pourpak A， Morris SW. Inhibition of the insulin-like rowth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer herapy approach [J]. Med Chem， 2009， 52(16): 4981-5004.
8.	孔虹，于成国. 端粒酶hTERT 基因转录调节的研究进展 [J].国外医学：临床生物化学与检验学分册， 2005， 26(8)：526-529.
9.	李松岗，刘峰，全志伟，等. 肝细胞癌临床病理特征与hTERT表达的关系 [J]. 江西医学院学报， 2008， 48(1)：67-70,73．.
10.	Liu JP， Chen W， Schwarer AP， et al. Telomerase in cancer immunotherapy J]. Biochim Biophys Acta， 2010， 1805(1): 35-42.
11.	乔雁翔，曾麟，曾文铤，等. 分期系统在中、晚期肝癌生存关系的评价 [J]. 临床医学工程， 2009， 16(8)：62-64．.
12.	杨秉辉，任正刚，汤钊猷. 关于原发性肝癌临床分期的研究和建议 [J]. 中华肝胆外科杂志， 1999， 5(1)：67．.
13.	Yao Z， Mishra L. Cancer stem cells and hepatocellular carcinoma J]. Cancer Biol Ther， 2009， 8(18): 1691-1698.
14.	Saalbach A， Hildebrandt G， Haustein UF， et al. The Thy-1/Thy-1 igand interaction is involved in binding of melanoma cells to activated hy-1-positive microvascular endothelial cells [J]. Microvasc Res， 2002， 64(1): 86-93.
15.	Gualberto A， Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions [J]. Oncogene， 2009， 28(34): 3009-3021.
16.	Atzori F， Traina TA， Ionta MT， et al. Targeting insulin-like growth factor type 1 receptor in cancer therapy [J]. Target Oncol，2009， 4(4): 255-266.
17.	Aleksic T， Chitnis MM， Perestenko OV， et al. Type 1 insulinlike growth factor receptor translocates to the nucleus of human tumor cells [J]. Cancer Res， 2010， 70(16): 6412-6419.
18.	Massoner P， Ladurner-Rennau M， Eder IE， et al. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer [J]. Br J Cancer， 2010，103(10): 1479-1484.
19.	Mitchel GC， Fillinger JL， Sittadjody S， et al. IGF1 activates cell cycle arrest following irradiation by reducing binding of Np63 to the p21 promoter [J]. Cell Death and Disease， 2010， 1(1): 1-10.
20.	张东，李开宗，窦科峰，等. 端粒酶逆转录酶基因hTERT 在肝细胞癌中的表达及端粒酶反义基因对人肝癌细胞HepG2 细胞凋亡的影响 [J]. 世界华人消化杂志，2005，13(2)：175-179．.
21.	范永卫. hTERT， c-myc， Ki-67 在肝癌组织中的表达及意义 [J].细胞与分子免疫学杂志， 2009， 25(4)：338-340．.
22.	Trevisani F， Frigerio M， Santi V， et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal [J]. Dig Liver Dis， 2010，42(5): 341-347.
23.	范永卫，万玉良，杨赤. 肝癌组织中hTERT 和c-myc 的表达及临床意义 [J]. 山东医药， 2009， 49(36)：47-48．.
24.	李华，王欣璐，杨扬，等. RNAi 靶向人端粒酶逆转录酶对人肝癌细胞的生长抑制作用 [J]. 南方医科大学学报，2008，28(8)：1323-1326．.
25.	Bazarov AV， Hines WC， Mukhopadhyay R， et al. Telomerase activation by c-myc in human mammary epithelial cells requires additional genomic changes [J]. Cell Cycle， 2009， 8(20): 3373-3378.
26.	Earl TM， Chapman WC. Conventional surgical treatment of hepatocellular carcinoma [J]. Clin Liver Dis， 2011， 15(2): 353-370.

1. Zhen FY， David WH， Michael NN， et al. Significance of CD90+cancer stem cells in human liver cancer [J]. Cancer Cell， 2008，13(2): 153-166.
2. Kelly PN， Dakic A， Adams JM， et al. Tumor growth need not be riven by rare cancer stem cells [J]. Science， 2007， 317(7): 337-337.
3. Bradley JE， Ramirez G， Hagood JS. Roles and regulation of Thy-1，a context-dependent modulator of cell phenotype [J]. Biofactors，2009， 35(3): 258-265.
4. 张华，高志红，刘春玲，等. Thy-1 肿瘤标记物在肝癌的表达及意义研究 [J]. 医学与哲学：临床决策论坛版， 2009， 30(5)：51-53．.
5. 牛坚，李向农，韩泽广. 运用siRNA 建立稳定低表达IGF1R基因的肝癌细胞株的实验研究 [J]. 中国普外基础与临床杂志， 2007， 14(6)：679-684．.
6. Maki RG. Small is beautiful: insulin-like growth factors and their ole in growth， development， and cancer [J]. J Clin Oncol，2010， 28(33): 4985-4995.
7. Li R， Pourpak A， Morris SW. Inhibition of the insulin-like rowth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer herapy approach [J]. Med Chem， 2009， 52(16): 4981-5004.
8. 孔虹，于成国. 端粒酶hTERT 基因转录调节的研究进展 [J].国外医学：临床生物化学与检验学分册， 2005， 26(8)：526-529.
9. 李松岗，刘峰，全志伟，等. 肝细胞癌临床病理特征与hTERT表达的关系 [J]. 江西医学院学报， 2008， 48(1)：67-70,73．.
10. Liu JP， Chen W， Schwarer AP， et al. Telomerase in cancer immunotherapy J]. Biochim Biophys Acta， 2010， 1805(1): 35-42.
11. 乔雁翔，曾麟，曾文铤，等. 分期系统在中、晚期肝癌生存关系的评价 [J]. 临床医学工程， 2009， 16(8)：62-64．.
12. 杨秉辉，任正刚，汤钊猷. 关于原发性肝癌临床分期的研究和建议 [J]. 中华肝胆外科杂志， 1999， 5(1)：67．.
13. Yao Z， Mishra L. Cancer stem cells and hepatocellular carcinoma J]. Cancer Biol Ther， 2009， 8(18): 1691-1698.
14. Saalbach A， Hildebrandt G， Haustein UF， et al. The Thy-1/Thy-1 igand interaction is involved in binding of melanoma cells to activated hy-1-positive microvascular endothelial cells [J]. Microvasc Res， 2002， 64(1): 86-93.
15. Gualberto A， Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions [J]. Oncogene， 2009， 28(34): 3009-3021.
16. Atzori F， Traina TA， Ionta MT， et al. Targeting insulin-like growth factor type 1 receptor in cancer therapy [J]. Target Oncol，2009， 4(4): 255-266.
17. Aleksic T， Chitnis MM， Perestenko OV， et al. Type 1 insulinlike growth factor receptor translocates to the nucleus of human tumor cells [J]. Cancer Res， 2010， 70(16): 6412-6419.
18. Massoner P， Ladurner-Rennau M， Eder IE， et al. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer [J]. Br J Cancer， 2010，103(10): 1479-1484.
19. Mitchel GC， Fillinger JL， Sittadjody S， et al. IGF1 activates cell cycle arrest following irradiation by reducing binding of Np63 to the p21 promoter [J]. Cell Death and Disease， 2010， 1(1): 1-10.
20. 张东，李开宗，窦科峰，等. 端粒酶逆转录酶基因hTERT 在肝细胞癌中的表达及端粒酶反义基因对人肝癌细胞HepG2 细胞凋亡的影响 [J]. 世界华人消化杂志，2005，13(2)：175-179．.
21. 范永卫. hTERT， c-myc， Ki-67 在肝癌组织中的表达及意义 [J].细胞与分子免疫学杂志， 2009， 25(4)：338-340．.
22. Trevisani F， Frigerio M， Santi V， et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal [J]. Dig Liver Dis， 2010，42(5): 341-347.
23. 范永卫，万玉良，杨赤. 肝癌组织中hTERT 和c-myc 的表达及临床意义 [J]. 山东医药， 2009， 49(36)：47-48．.
24. 李华，王欣璐，杨扬，等. RNAi 靶向人端粒酶逆转录酶对人肝癌细胞的生长抑制作用 [J]. 南方医科大学学报，2008，28(8)：1323-1326．.
25. Bazarov AV， Hines WC， Mukhopadhyay R， et al. Telomerase activation by c-myc in human mammary epithelial cells requires additional genomic changes [J]. Cell Cycle， 2009， 8(20): 3373-3378.
26. Earl TM， Chapman WC. Conventional surgical treatment of hepatocellular carcinoma [J]. Clin Liver Dis， 2011， 15(2): 353-370.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The Expression and Clinical Significance of CD90, IGF1R, and hTERT Protein in Hepatocellular Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content